Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

por Molinero, Luciana, Li, Yijin, Chang, Ching-Wei, Maund, Sophia, Berg, Maureen, Harrison, Jeanne, Fassò, Marcella, O’Hear, Carol, Hegde, Priti, Emens, Leisha A.
Publicado 2019

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

por Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Publicado 2015

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

por Budde, Lihua E., Assouline, Sarit, Sehn, Laurie H., Schuster, Stephen J., Yoon, Sung-Soo, Yoon, Dok Hyun, Matasar, Matthew J., Bosch, Francesc, Kim, Won Seog, Nastoupil, Loretta J., Flinn, Ian W., Shadman, Mazyar, Diefenbach, Catherine, O'Hear, Carol, Huang, Huang, Kwan, Antonia, Lin, Chi-Chung, Piccione, Emily C., Wei, Michael C., Yin, Shen, Barlett, Nancy L.
Publicado 2022